New drug approvals bring new treatment options and potential market opportunities. But what do they mean for companies planning their next generic or biosimilar development program? October 2026 had two important FDA approvals. Hovilpri (pritelivir) was approved for difficult-to-treat herpes simplex virus (HSV) infections and Hibsago (bepirovirsen) for chronic hepatitis B. Both drugs introduce new…
If you work in pharma, you hear IND, NDA, ANDA, and BLA all the time. They sound alike. But each one does a very different job.
Think of them as four applications to the US FDA. Together, they move a product from the lab to the US market. One lets you test a drug in…
Comparator drugs stay on the critical path of most clinical trials. If the comparator is late, in short supply, or lacks the right paperwork, the study stalls. That makes choosing a comparator sourcing partner one of the most important supply decisions a sponsor or CRO will make.
This blog covers why reliable comparator drug sourcing…
September 2026 brought 9 new FDA drug approvals, spanning rare neurological diseases, oncology, diabetes, diagnostic imaging, and movement disorders.
These approvals introduce new treatment options and highlight potential opportunities around market growth, exclusivity timelines, and future filing strategies for pharmaceutical companies.
Each new approval also brings potential future requirements for comparator and RLD sourcing, as…
Most conversations about clinical trial supply start with the same question: Will the investigational product or comparator drug reach the site on time?
The drug is central to the study, and any disruption to its supply can have serious consequences. But the drug is only one part of what a clinical site needs to keep…
The FDA approved 7 new drugs in August 2026. These approvals introduced new treatment approaches across sleep disorders, Alzheimer's disease diagnostics, oncology, rare diseases, autoimmune conditions, and hematology.
For pharma companies, each approval can signal future opportunities around market entry, exclusivity timelines, and filing strategies.
These approvals may also create future requirements for comparator sourcing,…
Comparator sourcing is one of the most consequential decisions in trial design. Get it wrong, and the results become hard to interpret, regulators question the design, or the supply team cannot get the product in time.
Comparator drug, active comparator, and placebo are often used as if they mean the same thing. They don't. Each…
Salim Shaikh, Founder and CEO of Spring Bio Solution, has authored a new article, "The Intelligence Gap in Comparator Sourcing: Why Clinical Trial Teams Are Still Flying Blind". This article examines one of the most costly yet overlooked problems in clinical research: the disconnect between comparator sourcing intelligence and trial design.
Sponsors invest millions in…
6 new drugs were approved by the FDA in the month of July. These drugs created new opportunities across oncology, immunology, cardiovascular care, ophthalmology, and CNS therapies.
They hint at new market opportunities, exclusivity timelines, and potential filing strategies for the decision-making teams.
Each new approval also signals a future comparator & RLD sourcing requirement,…
A drug can look brilliant in a single-arm study and fail completely once placed head-to-head against an active control. That gap between apparent effect and real effect is the entire reason controlled clinical trials exist.
Most participants improve for reasons that have nothing to do with the investigational product. Disease states fluctuate. Trial participants often…
